Company Profile

Nichi-Iko Pharmaceutical Co.,Ltd. is a Japan-based company principally engaged in the manufacture and sale of generic pharmaceutical products and other medical products. The Company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription issued by a doctor in a hospitals or clinics, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed.

Employees

2,656

Sector

Pharmaceuticals

More about the company

23-07-31	Nakakita Yakuhin Co., ltd. acquired Yakuhan Pharmaceutical Co., Ltd. from Nichi-Iko Pharmaceutical Co., Ltd.	CI
23-03-20	Nichi-Iko Pharmaceutical Co., Ltd.(TSE:4541) dropped from S&P Global BMI Index	CI
22-12-30	Japan Shares End Flat on Last Trading Day of 2022; Nichi-Iko Pharmaceutical Shares Plummet 24%	MT
22-12-29	Nichi-Iko Pharmaceutical Secures 98.5 Billion Yen of Debt Relief, Plans 20 Billion Yen Share Allotment; Shares Plunge 20%	MT
22-12-12	Nichi-Iko Pharmaceutical More Than Triples Fiscal H1 Profit	MT
22-11-13	Nichi-Iko Pharmaceutical Co., Ltd. announced that it expects to receive Ã‘19.998404811 billion in funding from Godo Kaisha JSD	CI
22-06-10	Japan Index Trades Steadily in Red; Round One Shares Gain 9% as May Sales Exceed Pre-Pandemic Level	MT
22-06-10	Chugai Appeals Tokyo Court's Dismissal of Patent Infringement Lawsuit Against Sawai, Nichi-iko Pharmaceutical	MT
22-05-30	Court Denies Chugai's Claim in Lawsuit Against Sawai, Nichi-iko	MT
22-03-10	Nichi-Iko Pharmaceutical's Nine-Month Profit Soars	MT
22-03-09	Nichi-Iko Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022	CI
22-02-25	Court Denies Chugai's Claim in Lawsuit Against Sawai, Nichi-iko and Nissan Chemical	MT
21-12-03	Nichi-Iko Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022	CI

22-03-09	Nichi Iko Pharmaceutical : 〔Delayed〕Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2022（IFRS）	PU
21-12-03	Nichi Iko Pharmaceutical : 〔Delayed〕Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2022 (IFRS)	PU
21-09-06	Nichi Iko Pharmaceutical : 〔Delayed〕Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022 (IFRS)	PU
21-02-18	Chugai Pharmaceutical : Refiles Patent Infringement Lawsuit concerning Edirol Capsules	AQ
20-11-30	Chugai Pharmaceutical : Files Patent Infringement Lawsuit concerning Edirol Capsules	AQ

20-07-22	EN DIRECT DES MARCHES : Valeo, Rubis, Antalis, GTT, Vente-Unique, Tesla, Apple, Boeing, ENI, Nestlé...
20-07-21	Nichi Iko Pharmaceutical : Le Japon approuve la dexaméthasone comme traitement contre le COVID-19
14-06-13	Japon-Sony pourrait sortir du JPX400, le rendement en vedette

Manager	Title	Age	Since
Shingo Iwamoto PSD	President	-	2023-03-28
Susumu Kanda PRN	Corporate Officer/Principal	63	2020-09-30
Osamu Mihara PRN	Corporate Officer/Principal	74	2013-03-31

Director	Title	Age	Since
Osamu Mihara BRD	Director/Board Member	74	2022-06-29
Susumu Kanda BRD	Director/Board Member	63	2022-06-29
Shingo Iwamoto BRD	Director/Board Member	-	2023-03-28

Nichi-Iko Pharmaceutical Co., Ltd. Stock

Stocks

4541

JP3687200000

Pharmaceuticals

Latest news: Nichi-Iko Pharmaceutical Co., Ltd.

Press Releases: Nichi-Iko Pharmaceutical Co., Ltd.

News in other languages: Nichi-Iko Pharmaceutical Co., Ltd.

Managers and Directors: Nichi-Iko Pharmaceutical Co., Ltd.

Specialty & Advanced Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICHI-IKO PHARMACEUTICAL CO., LTD.	-.--%	-.--%	-	-	171M
MERCK & CO., INC.	+0.78%	-1.78%	+78.70%	+34.77%	358B
MERCK KGAA	+0.61%	-0.75%	+23.72%	-20.42%	66.07B
HALOZYME THERAPEUTICS, INC.	+2.06%	+0.98%	+42.97%	+176.49%	12.31B
KYOWA KIRIN CO., LTD.	+1.71%	+2.24%	-5.39%	-16.52%	7.49B
SK BIOPHARMACEUTICALS CO., LTD.	+0.13%	-6.68%	-29.36%	-14.35%	4.48B
YUHAN CORPORATION	-2.52%	-3.38%	-35.21%	+7.50%	4.22B
BETTA PHARMACEUTICALS CO., LTD.	+2.21%	+0.06%	-32.05%	-13.89%	2.96B
SUPERNUS PHARMACEUTICALS, INC.	+0.24%	-1.64%	-5.93%	+41.57%	2.41B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+1.25%	-0.71%	-26.04%	-32.99%	1.95B
Average	+0.62%	-0.98%	+1.27%	+18.02%	51.04B
Weighted average by Cap.	+0.74%	-1.54%	+64.77%	+28.50%